GLP-1s and Addiction: What the 2026 Veterans Study Really Showed (and Didn't)

Headlines called GLP-1s an addiction cure. The study underneath is genuinely interesting — and considerably more careful than the coverage. Here's the clinical read.

Reviewed for clinical accuracy · Updated August 2026

In early 2026, a study published in BMJ examined health records of more than 600,000 US veterans with type 2 diabetes and reported something striking: those prescribed GLP-1 receptor agonists had a lower risk of developing substance use disorders — across major drug classes — than similar patients on a different diabetes medication class (SGLT2 inhibitors). Among patients who already had substance use disorders, GLP-1 users had fewer overdoses and hospitalizations.

It's a large, well-conducted piece of observational research, and it fits a pattern patients have reported anecdotally for years: on these medications, the pull toward alcohol, nicotine, and other substances seems to quiet down alongside the pull toward food. But before anyone reframes a weight-loss drug as addiction medicine, it's worth being precise about what this evidence is and isn't.

Why the biology is plausible

GLP-1 receptors aren't confined to the gut and pancreas. They're present in brain regions that govern reward, impulse control, and craving — the same circuitry addictive substances hijack. The leading hypothesis is that GLP-1 activation dampens reward signaling generally: food becomes less compelling, and so, apparently, do other reinforcers. Animal studies have shown GLP-1 drugs reduce alcohol and drug self-administration for years. The human observational data now points the same direction.

What the study can't tell us

• It's observational. Patients weren't randomized. People prescribed GLP-1s may differ from comparison patients in ways records can't fully capture — engagement with care, health behaviors, socioeconomic factors.
• It's a specific population. Older, mostly male veterans with type 2 diabetes. The findings may not transfer cleanly to other groups.
• Association isn't treatment. A lower risk in records is not the same as a demonstrated ability to treat an existing addiction in a randomized trial.

What it means for patients today

Randomized trials of GLP-1s in alcohol use disorder and smoking are underway, and this is one of the most closely watched frontiers in the field. For now, the practical takeaways are modest but real:

• If you're on a GLP-1 for weight or diabetes and notice reduced interest in alcohol or nicotine, that's a recognized phenomenon, not your imagination — and worth mentioning to your prescriber as a data point.
• If you have both obesity and concerns about drinking, the choice of weight-loss medication is a reasonable thing to discuss with your doctor in light of this research — as one factor among many, on-label, for the approved indication.
• Nobody should seek a GLP-1 as addiction treatment. The evidence isn't there yet, and the approved indications don't cover it.

If you're considering GLP-1 therapy for an approved use

Where these medications are unambiguously indicated — chronic weight management, type 2 diabetes, and the growing list of related conditions — licensed telehealth clinicians can evaluate you and discuss the full risk-benefit picture, including questions raised by research like this:

The bottom line

The veterans study is a strong signal in a research story that's still being written. The reward circuitry link is biologically real; whether it translates into approved addiction treatment awaits randomized trials. Until then: interesting science, cautious clinical conclusions, and no off-label experiments.